Oculus Innovative Sciences Announces Fiscal Second Quarter 2012 Financial Results and Conference Call
October 21, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Oct. 21, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal second quarter 2012, ended September 30,...
Oculus Innovative Sciences Licenses Global Rights for Endotracheal Tube From National Institutes of Health to Reduce Ventilator-Associated Pneumonia
September 20, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
Ventilator-associated pneumonia (VAP) afflicts over 300,000 patients per year in the United States; responsible for $12 billion in extended patient length of stay in U.S. hospitals
Patented...
Oculus Innovative Sciences Reports Record First Quarter Financial Results
August 04, 2011 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced financial results for the first quarter of fiscal year 2012, ended June 30, 2011....
Oculus Innovative Sciences, Inc. Announces a Multi-Year Licensing Agreement With Eloquest Healthcare(R) for Microcyn(R)-Based Wound Care Products
July 27, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
FERNDALE, Mich. and PETALUMA, Calif., July 27, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced a multi-year licensing agreement with Eloquest Healthcare, a...
Oculus Innovative Sciences Announces Fiscal First Quarter 2012 Financial Results and Conference Call
July 21, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., July 21, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal first quarter 2012, ended June 30, 2011,...
AmDerma Pharmaceuticals Exercises Option to License Rights to Oculus Innovative Sciences Microcyn(R)-Based Acne Drug Candidate
June 28, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif. and BRIDGEWATER, N.J., June 28, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), a commercial healthcare company that designs, produces and markets safe and...
Oculus Innovative Sciences Reports Record Fourth Quarter, Beating Quarterly Guidance; and Reports Year-End Revenue for Fiscal Year Ended March 31, 2011
June 02, 2011 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., June 2, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) today announced financial and operating results for the fourth quarter of fiscal year 2011, ended...
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2011 Financial Results and Conference Call
May 25, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., May 25, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), today announced that the financial results for its fiscal fourth quarter 2011, ended March 31, 2011,...
Oculus Innovative Sciences Beats Fourth Quarter Guidance and Provides Commercialization Update
May 10, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
Company Beats Fourth Quarter (Ending March 31, 2011) Guidance for:
Revenue
Net Loss Minus Non-Cash Expenses, and
Cash Operating Expenses
Innovacyn, Oculus' Animal...
Oculus Innovative Sciences Posts CEO's Presentation From the Roth Capital Partners 23rd Annual Growth Stock Conference
March 24, 2011 08:08 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 24, 2011 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS), innovator and developer of products based upon the Microcyn® Technology platform, today made...